Document is current
Any future updates will be listed below
-
Authors
Bastian, Hervé https://orcid.org/0009-0001-0589-9647
Lounnas-Mourey, Nadia
Heimendinger, Pierre
Hsu, Benjamin L.
Schreeb, Katharina H.
Chapman, Claire
Culme-Seymour, Emily
Atkinson, Gillian F.
Cantarovich, Diego
-
Funding
Funding for this research was provided by:
Sangamo Therapeutics
- License Information
-
More Information
Article History
Received: 10 May 2023
Accepted: 4 July 2023
First Online: 13 July 2023
Declarations
:
: The protocol, protocol amendments, informed consent form and other relevant study documents were reviewed and approved according to local regulations by an independent ethics committee (Comité de Protection des Personnes Ile-de-France VII, France; reference numbers 2018-A02923-52 and protocol # 18–092 (CPP IDF VII)). All patients provided written informed consent before participation. Commercially purchased leukopheresates from Charles River were collected in U.S. Food and Drug Administration-registered collection centres from healthy human donors who had consented under an institutional review board-approved protocol.
: Not applicable.
: The TX200-KT01 study was sponsored by Sangamo Therapeutics. HB, NLM, BLH, KHS, CC, ECS and GFA are full-time employees of Sangamo Therapeutics. PH was formerly a full-time employee of Sangamo Therapeutics when the study was conducted and the manuscript drafted. DC was the principal investigator of the TX200-KT01 study.
